Correct. They focused on the high responder, high risk diabetic population to maximize apabetalone benefit and minimize the size and time needed for the trial. Hindsight is always 20/20. Knowing what we know now, BETonMACE should have had double the patients and double the events. Alternatively, having a stage 3 CKD requirement for all patients. No doubt in my mind that apabetalone would elicit benefit in those with no diabetes and those with normal cholesterol. However, a successful trial requires the right mix of size, length, endpoint, and effect size.

BDAZ